Immuneering presents AACR data on atebimetinib in pancreatic cancer study
Exploratory analyses linked body-weight maintenance during treatment with longer survival; survival appeared similar across tumor-shrinkage depths.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer
Stable or increased weight was twice as common among pancreatic cancer patients in the atebimetinib + mGnP study, compared to those in a benchmark study -- Patients with stable or increased weight at three months had significantly longer overall survival than patients who lost weight at three mon…
Immuneering presents pancreatic cancer data at AACR
Immuneering said it presented data at the 2026 AACR Conference on Pancreatic Cancer supporting atebimetinib’s mechanisms designed to extend survival in pancreatic cancer.